Systematic reviews of antihypertensive drugs: A review of publication trends, characteristics, and quality
Autor: | H Esam, Abdul Salam, Rupasvi Dhurjati, Mark D. Huffman, Raju Kanukula, Soumyadeep Bhaumik, Sindhujareddy Chevireddy, Emily Atkins, Anthony Rodgers, Rupa Aerram |
---|---|
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
Endocrinology Diabetes and Metabolism High impact factor systematic reviews Angiotensin-Converting Enzyme Inhibitors Angiotensin II Receptor Blockers 030204 cardiovascular system & hematology law.invention mapping review Angiotensin Receptor Antagonists 03 medical and health sciences 0302 clinical medicine Bias Randomized controlled trial law Internal medicine risk of bias parasitic diseases Internal Medicine medicine Humans 030212 general & internal medicine Randomized Controlled Trials as Topic Review Paper business.industry Standard methods antihypertensive agents Systematic Reviews and Meta‐analyses Systematic review Hypertension Cardiology and Cardiovascular Medicine business |
Zdroj: | The Journal of Clinical Hypertension |
ISSN: | 1751-7176 1524-6175 |
Popis: | This review presents publication trends, characteristics, and quality of systematic reviews (SRs) of randomized controlled trials (RCTs) of antihypertensive drugs (AHTDs). Between 1985 and 2017, 1,173 SRs were published, and in the last 20 years, 10, 35, and 116 were published in the year 1996, 2006, and 2016, respectively. Angiotensin‐converting enzyme inhibitors/angiotensin II receptor blockers were the most common class of drugs studied. Fourteen percent of the SRs were prospectively registered/published protocol. Three‐fourth of the SRs did not report a full search strategy, and 45% did not report a PRISMA or similar diagram. Of the 34 SRs published in the five high impact factor journals in the last 10 years, 15%, 21%, and 65% have unclear, low, and high risk of bias, respectively. There has been a steady increase in the publication of SRs of RCTs of AHTDs. However, adherence to standard methods of conduct and reporting continues to be low. Between 1985 and 2017, 1,173 SRs of antihypertensive drugs (AHTDs) were published. Angiotensin‐converting enzyme inhibitors/angiotensin II receptor blockers were the most common class of drugs studied. Fourteen percent of the SRs were prospectively registered/published protocol. Three‐fourth of the SRs did not report a full search strategy, and 45% did not report PRISMA diagram. Of the 34 SRs published in the five high impact factor journals in the last 10 years, 15%, 21%, and 65% have unclear, low, and high risk of bias, respectively. There has been a steady increase in the publication of SRs of RCTs of AHTDs. However, adherence to standard methods of conduct and reporting continues to be low. |
Databáze: | OpenAIRE |
Externí odkaz: |